Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

In the global phase III RELAY study, ramucirumab plus erlotinib (RAM + ERL) demonstrated superior progression‐free survival (PFS) to placebo plus erlotinib (PL + ERL) in untreated patients with epidermal growth factor receptor (EGFR) mutation‐positive metastatic non‐small‐cell lung cancer (NSCLC) (h...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Makoto, Seto, Takashi, Reck, Martin, Garon, Edward B., Chiu, Chao‐Hua, Yoh, Kiyotaka, Imamura, Fumio, Park, Keunchil, Shih, Jin‐Yuan, Visseren‐Grul, Carla, Frimodt‐Moller, Bente, Zimmermann, Annamaria, Homma, Gosuke, Enatsu, Sotaro, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734014/
https://www.ncbi.nlm.nih.gov/pubmed/32954593
http://dx.doi.org/10.1111/cas.14655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734014/
https://www.ncbi.nlm.nih.gov/pubmed/32954593
http://dx.doi.org/10.1111/cas.14655

Ejemplares similares